EQL-101
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
EQL-101 is a non-hallucinogenic ibogaine analogue which is under development for the treatment of substance use disorders such as opioid use disorder. It is said to preserve the therapeutic activity of ibogaine but to lack its hallucinogenic effects as well as certain adverse effects like cardiotoxicity. The drug is under development by Equulus Therapeutics. As of 2025, it is in the discovery or preclinical research stage of development.
EQL-101 is a non-hallucinogenic ibogaine analogue which is under development for the treatment of substance use disorders such as opioid use disorder. It is said to preserve the therapeutic activity of ibogaine but to lack its hallucinogenic effects as well as certain adverse effects like cardiotoxicity. The drug is under development by Equulus Therapeutics. As of 2025, it is in the discovery or preclinical research stage of development. EQL-101 - Equulus Therapeutics
Text derived from https://en.wikipedia.org/w/index.php?oldid=1335258031 under CC BY-SA 4.0; modifications have been made.